Keynote presentations 2018

Plenum session 1: A Visionary Outlook

This session drew the broad picture of why this summit was neeeded; the challenges ahead, including those from an equity of access and economic perspective. It also  shed light on the many opportunities, for example in bio-banks, data and registries that can create a positive trajectory forward.

Speakers:

  • Dr. Susan Galbraith, Head of Oncology, iMed, Innovative Medicines, AstraZeneca
  • Professor Klas Kärre, Chairman, the Swedish Cancer Society’s research committee
  • Professor Max Parkin, Nuffield Dept. of Population Health, Oxford University

  • Professor Max Parkin, Nuffield Institute, Oxford University

  • Dr. Susan Galbraith, Innovative Medicines, AstraZeneca

  • Professor Klas Kärre, Swedish Cancer Society

  • Plenary Discussion - A Visionary Outlook

Plenum Session 2: Patients as a driving force to develop care

In many parts of the world, patients and their kin claim an individual relation to healthcare, focusing on the patient. Expectations are high on receiving an individualized treatment; on transparency and on access to your own data. Many also want to contribute to the development of cancer care with their own data, generated inside or outside healthcare.

How will this development influence the relationship between healthcare and the individual patient? How can healthcare take advantage of the research advancements in precision medicine? How should patients be involved? And is a patient focus only a high income luxury or a possibility everywhere?

Speakers:

  • Gregory C Simon, Biden Cancer Initiative

  • Dr. Ingela Franck Lissbrant, National Prostate Cancer Registry

  • Marie Ennis O'Connor, Patient Empowerment Foundation

  • Kelechi Eguzo, MD, MPH, Nigerian Christian Hospital and Marjorie Bash Foundation

  • Plenum Discussion: Patients as a driving force to develop care

Plenum session 3: Access to treatments and diagnostics

Access to new cancer diagnostics and treatments is extremely unequally distributed, especially between high- and low income countries. Pharma industry has been strongly criticized for charging too much. But is it really that simple? Can we secure both access and an innovating industry? 

Speakers: 

  • Dr. Mariângela Simão, Assistant Director General, WHO

  • Prof. Arnie Purushotham, King’s College London; Tata Trust, Mumbai

  • Thomas B. Cueni, Director General, IFPMA

  • Plenary Discussion - Access to treatments and diagnostics

Plenum session 4: The threats against public health - Governance versus behavioural changes

Lifestyle is responsible for 30 % of all cancer cases. Tobacco alone may explain 20 %. Is it responsible to lay the burden of changing lifestyle on the individual only? What can can international governance and politics achieve?

Speakers:

Conclusions and Take Home Messages